News

Filter

Ariad co-opts Otsuka for Iclusig in Japan and other Asian countries

Ariad co-opts Otsuka for Iclusig in Japan and other Asian countries

24-12-2014

US specialty pharma firm Ariad Pharmaceuticals has entered into an agreement for Japan’s Otsuka Pharmaceuticals…

Ariad PharmaceuticalsAsia-PacificBiotechnologyIclusigJapanLicensingOncologyOtsuka PharmaceuticalResearch

Ariad enlists Medison to market Iclusig in Israel

Ariad enlists Medison to market Iclusig in Israel

06-08-2014

US specialty pharma firm Ariad Pharmaceuticals has granted Israel’s Medison Pharma exclusive rights…

AlkynesAriad PharmaceuticalsIclusigIsraelLicensingOncologyOrganofluoridesPharmaceuticalPiperazines

Merck returns rights to ridaforolimus to Ariad, whose 4th-qtr net loss widens

Merck returns rights to ridaforolimus to Ariad, whose 4th-qtr net loss widens

26-02-2014

US pharma giant Merck & Co has told partner Ariad Pharmaceutical that it is terminating its license agreement…

Ariad PharmaceuticalsFinancialLicensingMerck & CoOncologyPharmaceuticalridaforolimus

Ariad Pharma plans commercialization of Iclusig in Australia

Ariad Pharma plans commercialization of Iclusig in Australia

28-01-2014

US specialty pharma firm Ariad Pharmaceuticals has signed an agreement with Specialised Therapeutics…

Ariad PharmaceuticalsAsia-PacificAustraliaIclusigLicensingOncologyPharmaceuticalSpecialised Therapeutics Australia

ARIAD in three exclusive out-licensing deals for ARGENT cell-signaling regulation technology

21-04-2011

USA-based ARIAD Pharmaceuticals (Nasdaq: ARIA) has announced execution of three exclusive out-license…

Ariad PharmaceuticalsLicensingPharmaceuticalResearch

ARIAD rises on decision to co-promote ridaforolimus with Merck & Co on US approval

21-03-2011

ARIAD Pharmaceuticals (Nasdaq: ARIA) saw its shares jump 5.5% to $5.93 when it revealed that it has opted…

Ariad PharmaceuticalsLicensingMarkets & MarketingMerck & CoNorth AmericaOncologyPharmaceuticalponatinibridaforolimus

Merck & Co restructures cancer drug deal with Ariad, worth up to $583 million; has Fosamax injury case dismissed

06-05-2010

Following an announcement earlier this year by US drug giant Merck & Co that it was reviewing its research…

Anti-Arthritics/RheumaticsAriad PharmaceuticalsFosamaxLicensingMerck & CoOncologyPharmaceuticalRegulationridaforolimus

Back to top